Anakinra

Summary

Anakinra (CHEMBL1201570) is an approved protein (ATC L04AC03); indicated across 63 conditions including rheumatoid arthritis and immune system disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L04AC03
• Indications: 63 conditions
• Clinical trials: 156

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201570
Name	Anakinra
Type	Protein
Max phase	4
ATC	L04AC03

Also known as: Alta-2530, Alta2530, AMG-719, Anakinra, Antril, Kineret, Osp-101, R-METHUIL-1RA, ANAKINRA

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	Interleukin-1 receptor, type I	Inhibition	7.82

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

63 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
immune system disorder	4	MONDO:0005046	EFO:0000540
cryopyrin-associated periodic syndrome	4	MONDO:0016168	Orphanet:47045
COVID-19	4	MONDO:0100096	MONDO:0100096
Kawasaki disease	3	MONDO:0012727	EFO:0004246
metabolic syndrome X	3	MONDO:0011565	EFO:0000195
pericarditis	3	MONDO:0005904	EFO:0007427
adult-onset Still disease	3	MONDO:0019355	EFO:0007135
temporal arteritis	3	MONDO:0008538	EFO:1001209
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
acute myocardial infarction	3	MONDO:0004781	EFO:0008583
pneumonia	3	MONDO:0005249	EFO:0003106
influenza	3	MONDO:0005812	EFO:0007328
allergic contact dermatitis	3	MONDO:0006525	EFO:1000668
familial Mediterranean fever	3	MONDO:0018088	MONDO:0018088
diabetes mellitus	2	MONDO:0005015	EFO:0000400
heart failure	2	MONDO:0005252	EFO:0003144
juvenile idiopathic arthritis	2	MONDO:0011429	EFO:0002609
chronic kidney disease	2	MONDO:0005300	EFO:0003884
myalgic encephalomeyelitis/chronic fatigue syndrome	2	MONDO:0005404	EFO:0004540
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
uveitis	2	MONDO:0020283	EFO:1001231
dermatomyositis	2	MONDO:0016367	EFO:0000398
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
gout	2	MONDO:0005393	EFO:0004274
inclusion body myositis	2	MONDO:0007827	EFO:0007323
alcoholic hepatitis	2	MONDO:0001505	EFO:1001345
macrophage activation syndrome	2	MONDO:0015545	EFO:1001806
polycystic ovary syndrome	2	MONDO:0008487	EFO:0000660
neoplasm of mature B-cells	2	MONDO:0004949	EFO:0000096
brain injury	2	MONDO:0043510	MONDO:0043510
intracerebral hemorrhage	2	MONDO:0013792	EFO:0005669
hypoglycemia	2	MONDO:0004946	HP:0001943
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
osteoarthritis	2	MONDO:0005178	MONDO:0005178
Dengue hemorrhagic fever	2	MONDO:0005358	EFO:0004227
acute respiratory distress syndrome	2	MONDO:0006502	EFO:1000637
viral infectious disease	2	MONDO:0005108	EFO:0000763
Meniere disease	2	MONDO:0007972	EFO:0006862
cystic fibrosis	2	MONDO:0009061	MONDO:0009061
mucopolysaccharidosis type 2	2	MONDO:0010674	MONDO:0010674
pulmonary arterial hypertension	1	MONDO:0015924	EFO:0001361
neoplasm	1	MONDO:0005070	EFO:0000616
HIV infectious disease	1	MONDO:0005109	EFO:0000764
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
smoldering plasma cell myeloma	1	MONDO:0005235	EFO:0003073
hearing loss disorder	1	MONDO:0005365	EFO:0004238
blepharitis	1	MONDO:0004785	EFO:0009536
pulmonary hypertension	1	MONDO:0005149	MONDO:0005149
breast neoplasm	1	MONDO:0021100	MONDO:0007254
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
rectal cancer	1	MONDO:0006519	EFO:1000657
asthma	1	MONDO:0004979	MONDO:0004979
multiple sclerosis	1	MONDO:0005301	MONDO:0005301
endometriosis	0	MONDO:0005133	EFO:0001065
chronic granulomatous disease	0	MONDO:0018305	MONDO:0018305

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 156.

Phase distribution

Phase	Trials
PHASE2	59
PHASE3	20
PHASE1/PHASE2	20
PHASE1	17
Not specified	15
PHASE2/PHASE3	13
PHASE4	6
EARLY_PHASE1	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06624436	PHASE4	RECRUITING	Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
NCT06666335	PHASE4	NOT_YET_RECRUITING	A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
NCT06697431	PHASE4	NOT_YET_RECRUITING	Non Inferiority KawasakI Trial With Anakinra
NCT00111410	PHASE4	COMPLETED	Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)
NCT02219828	PHASE4	COMPLETED	AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)
NCT02236481	PHASE4	TERMINATED	Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes
NCT02735707	PHASE3	RECRUITING	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT04381936	PHASE3	RECRUITING	Randomised Evaluation of COVID-19 Therapy
NCT04656184	PHASE3	RECRUITING	A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
NCT05267821	PHASE2/PHASE3	RECRUITING	Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05805930	PHASE3	NOT_YET_RECRUITING	Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
NCT05814159	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Anakinra in Japanese Patients With Still’s Disease (SJIA and AOSD)
NCT05926505	PHASE2/PHASE3	RECRUITING	Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
NCT06336733	PHASE3	RECRUITING	Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
NCT07281027	PHASE3	NOT_YET_RECRUITING	COMparison Between Anakinra and Tocilizumab in NORSE - COMBAT-NORSE
NCT07371689	PHASE3	NOT_YET_RECRUITING	ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS
NCT00117091	PHASE3	COMPLETED	Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)
NCT00339157	PHASE2/PHASE3	COMPLETED	Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
NCT00711503	PHASE2/PHASE3	COMPLETED	Anti-Interleukin-1 in Diabetes Action
NCT00789724	PHASE3	COMPLETED	Anakinra to Prevent Post-infarction Remodeling
NCT01165008	PHASE2/PHASE3	COMPLETED	Anakinra in Myositis
NCT01705756	PHASE3	COMPLETED	Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever
NCT01809132	PHASE2/PHASE3	COMPLETED	Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
NCT01950299	PHASE2/PHASE3	COMPLETED	Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
NCT02108210	PHASE2/PHASE3	COMPLETED	Cytokine Inhibition in Chronic Fatigue Syndrome Patients
NCT02227420	PHASE3	COMPLETED	Effects of IL-1 Beta on the HPA-axis in Obese Persons
NCT02672592	PHASE3	COMPLETED	Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome
NCT02902731	PHASE3	TERMINATED	Giant Cell Arteritis and Anakinra Trial
NCT03018834	PHASE2/PHASE3	COMPLETED	Anakinra Versus Placebo for the Treatment of Acute MyocarditIS
NCT03265132	PHASE3	TERMINATED	A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still’s Disease (SJIA and AOSD)
NCT04324021	PHASE2/PHASE3	TERMINATED	Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
NCT04330638	PHASE3	COMPLETED	Treatment of COVID-19 Patients With Anti-interleukin Drugs
NCT04362111	PHASE3	COMPLETED	Early Treatment of Cytokine Storm Syndrome in Covid-19
NCT04424056	PHASE3	UNKNOWN	A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
NCT04443881	PHASE2/PHASE3	COMPLETED	Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
NCT04643678	PHASE2/PHASE3	COMPLETED	Anakinra in the Management of COVID-19 Infection
NCT04680949	PHASE3	COMPLETED	suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19
NCT04898231	PHASE2/PHASE3	COMPLETED	MIS-C Comparative Effectiveness Study
NCT05498467	PHASE3	COMPLETED	The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
NCT03587701	PHASE2	RECRUITING	Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere’s Disease and Autoimmune Inner Ear Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).